A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

NCT04449874 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Colorectal Cancer
Advanced Solid Tumors

Interventions

DRUG: GDC-6036
DRUG: Atezolizumab
DRUG: Cetuximab
DRUG: Bevacizumab
DRUG: Erlotinib
DRUG: GDC-1971
DRUG: Inavolisib

Sponsor

Genentech, Inc.